Ongoing Securities Investigation into Aquestive Therapeutics, Inc. (AQST) - Contact Levi & Korsinsky
New York, New York--(Newsfile Corp. - January 19, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive Therapeutics, Inc.") concerning potential violations of the federal securities laws. What Happened? On January 9, 2026, Aquestive announced it received a letter from the FDA, identifying deficiencies in its NDA application that preclude labeling discussions and post-market commitments for Anaphylm, for...
2026-01-19 12:43 AM EST
Ongoing Investigation into Galectin Therapeutics Inc. (GALT): Contact Levi & Korsinsky About Potential Fraud
New York, New York--(Newsfile Corp. - January 19, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Galectin Therapeutics Inc. (NASDAQ: GALT) ("Galectin Therapeutics Inc.") concerning potential violations of the federal securities laws. Galectin issued a press release on December 19, 2025, "announc[ing] that the U.S. Food and Drug Administration (FDA) has provided a written response, and subsequent communications, to the Company's previously submitted...
2026-01-19 12:32 AM EST
Levi & Korsinsky Investigates Possible Securities Fraud by Corcept Therapeutics Incorporated (CORT)
New York, New York--(Newsfile Corp. - January 19, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Corcept Therapeutics Incorporated (NASDAQ: CORT) ("Corcept Therapeutics Incorporated") concerning potential violations of the federal securities laws. What Happened? On December 31, 2025, Corcept announced it received a CRL from the FDA, denying approval of Corcept's new drug application for relacorilant as a treatment for patients with hypertension...
2026-01-19 12:27 AM EST
Investigation Opened on Behalf of Ultragenyx Pharmaceutical Inc. (RARE) Shareholders - Contact Levi & Korsinsky
New York, New York--(Newsfile Corp. - January 19, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) ("Ultragenyx Pharmaceutical Inc.") concerning potential violations of the federal securities laws. What Happened? On December 29, 2025, Ultragenyx announced the results from both its Phase III Orbit and Cosmic studies, both focused on the effectiveness of setrusumab (UX143) in Osteogenesis Imperfecta. Both...
2026-01-19 12:25 AM EST
MREO Investor Notice: Levi & Korsinsky Investigates Mereo BioPharma Group plc for Securities Law Violations
New York, New York--(Newsfile Corp. - January 19, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Mereo BioPharma Group plc (NASDAQ: MREO) ("Mereo BioPharma Group plc") concerning potential violations of the federal securities laws. On December 29, 2025, before the market opened, Mereo announced results from its Phase 3 ORBIT and COSMIC studies for setrusumab (UX143) in Osteogenesis Imperfecta (OI). The company reported that neither study failed to...
2026-01-19 12:13 AM EST
Lost Money on Apogee Enterprises, Inc. (APOG)? Contact Levi & Korsinsky About Investigation
New York, New York--(Newsfile Corp. - January 19, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Apogee Enterprises, Inc. (NASDAQ: APOG) ("Apogee Enterprises, Inc.") concerning potential violations of the federal securities laws. On January 7, 2026, before the market opened, APOG published fiscal third quarter 2026 financial results highlighting the company's performance expectations for the coming years. APOG disclosed its gross margin decreased to...
2026-01-19 12:10 AM EST
Lost Money on Vanda Pharmaceuticals Inc. (VNDA)? Contact Levi & Korsinsky About Fraud Investigation
New York, New York--(Newsfile Corp. - January 15, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Vanda Pharmaceuticals Inc. ("Vanda Pharmaceuticals Inc.") (NASDAQ: VNDA) concerning potential violations of the federal securities laws. Vanda issued a press release on January 8, 2026, "announc[ing] that it has received a decision letter from the U.S. Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER) concluding that the...
2026-01-15 11:27 AM EST
DLTH ACTIVE INVESTIGATION: Lost Money on Duluth Holdings Inc.? Contact Levi & Korsinsky Now
New York, New York--(Newsfile Corp. - January 14, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Duluth Holdings Inc. ("Duluth Holdings Inc.") (NASDAQ: DLTH) concerning potential violations of the federal securities laws. Duluth issued a press release on December 16, 2025, announcing its financial results for the third quarter of 2025. Among other items, Duluth lowered its nets sales guidance to a range of $555 million to $565 million, down from...
2026-01-14 1:20 PM EST
Lost Money on CorMedix Inc. (CRMD)? Contact Levi & Korsinsky About Fraud Investigation
New York, New York--(Newsfile Corp. - January 14, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into CorMedix Inc. ("CorMedix Inc.") (NASDAQ: CRMD) concerning potential violations of the federal securities laws. On January 8, 2026, before the market opened, CorMedix published preliminary fourth quarter and full year 2025 results disclosing that its major revenue driver DefenCath would change its reimbursement policy change beginning on July 1, 2026....
2026-01-14 9:58 AM EST
Levi & Korsinsky Investigates Possible Securities Fraud by Aquestive Therapeutics, Inc. (AQST)
New York, New York--(Newsfile Corp. - January 14, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Aquestive Therapeutics, Inc. ("Aquestive Therapeutics, Inc.") (NASDAQ: AQST) concerning potential violations of the federal securities laws. What Happened? On January 9, 2026, Aquestive announced it received a letter from the FDA, identifying deficiencies in its NDA application that preclude labeling discussions and post-market commitments for Anaphylm, for...
2026-01-14 9:55 AM EST
Securities Investigation: Levi & Korsinsky Investigates Galectin Therapeutics Inc. (GALT) on Behalf of Investors
New York, New York--(Newsfile Corp. - January 14, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Galectin Therapeutics Inc. ("Galectin Therapeutics Inc.") (NASDAQ: GALT) concerning potential violations of the federal securities laws. Galectin issued a press release on December 19, 2025, "announc[ing] that the U.S. Food and Drug Administration (FDA) has provided a written response, and subsequent communications, to the Company's previously submitted...
2026-01-14 9:51 AM EST
Investigation Alert: Levi & Korsinsky Investigates Securities Fraud Claims Against Ultragenyx Pharmaceutical Inc. (RARE)
New York, New York--(Newsfile Corp. - January 14, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Ultragenyx Pharmaceutical Inc. ("Ultragenyx Pharmaceutical Inc.") (NASDAQ: RARE) concerning potential violations of the federal securities laws. What Happened? On December 29, 2025, Ultragenyx announced the results from both its Phase III Orbit and Cosmic studies, both focused on the effectiveness of setrusumab (UX143) in Osteogenesis Imperfecta. Both...
2026-01-14 9:48 AM EST
Investors in AST SpaceMobile, Inc. (ASTS) Warned of Potential Securities Fraud - Contact Levi & Korsinsky Today
New York, New York--(Newsfile Corp. - January 14, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into AST SpaceMobile, Inc. ("AST SpaceMobile, Inc.") (NASDAQ: ASTS) concerning potential violations of the federal securities laws. On December 15, 2025, it was revealed that AST's launch of its BlueBird 6 was delayed. The launch, which was scheduled for December 15, 2025, was tentatively pushed back to December 21, 2025. AST's BlueBird 6, the Company's...
2026-01-14 9:45 AM EST
Investigation Alert: Levi & Korsinsky Investigates Securities Fraud Claims Against Corcept Therapeutics Incorporated (CORT)
New York, New York--(Newsfile Corp. - January 14, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Corcept Therapeutics Incorporated ("Corcept Therapeutics Incorporated") (NASDAQ: CORT) concerning potential violations of the federal securities laws. What Happened? On December 31, 2025, Corcept announced it received a CRL from the FDA, denying approval of Corcept's new drug application for relacorilant as a treatment for patients with hypertension...
2026-01-14 9:38 AM EST
Ongoing Securities Investigation into Mereo BioPharma Group plc (MREO) - Contact Levi & Korsinsky
New York, New York--(Newsfile Corp. - January 14, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Mereo BioPharma Group plc ("Mereo BioPharma Group plc") (NASDAQ: MREO) concerning potential violations of the federal securities laws. On December 29, 2025, before the market opened, Mereo announced results from its Phase 3 ORBIT and COSMIC studies for setrusumab (UX143) in Osteogenesis Imperfecta (OI). The company reported that neither study failed to...
2026-01-14 9:34 AM EST
RZLT ALERT: Levi & Korsinsky Investigates Rezolute, Inc. for Possible Securities Fraud Violations
New York, New York--(Newsfile Corp. - January 14, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Rezolute, Inc. ("Rezolute, Inc.") (NASDAQ: RZLT) concerning potential violations of the federal securities laws. On December 11, 2025, before the market opened, Rezolute announced topline results from its Phase 3 sunRIZE study evaluating ersodetug in patients with congenital hyperinsulinism. The company reported that the study did not meet its primary...
2026-01-14 9:30 AM EST
Ongoing Investigation: Apogee Enterprises, Inc. (APOG) May Have Misled Shareholders - Levi & Korsinsky Investigates
New York, New York--(Newsfile Corp. - January 14, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Apogee Enterprises, Inc. ("Apogee Enterprises, Inc.") (NASDAQ: APOG) concerning potential violations of the federal securities laws. On January 7, 2026, before the market opened, APOG published fiscal third quarter 2026 financial results highlighting the company's performance expectations for the coming years. APOG disclosed its gross margin decreased to...
2026-01-14 9:26 AM EST
Lost Money on MoonLake Immunotherapeutics (MLTX)? Contact Levi & Korsinsky Before December 15, 2025 to Join Class Action
New York, New York--(Newsfile Corp. - November 19, 2025) - If you suffered a loss on your MoonLake Immunotherapeutics (NASDAQ: MLTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/moonlake-lawsuit-submission-form?prid=178166&wire=5&utm_campaign=12 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced...
2025-11-19 9:12 AM EST
Investigation Opened on Behalf of Ardent Health, Inc. (ARDT) Shareholders - Contact Levi & Korsinsky
New York, New York--(Newsfile Corp. - November 18, 2025) - Levi & Korsinsky notifies investors that it has commenced an investigation of Ardent Health, Inc. ("Ardent Health, Inc.") (NYSE: ARDT) concerning possible violations of federal securities laws. Ardent issued a press release on November 12, 2025, announcing its financial results for the third quarter of 2025. In connection with that release, the Company disclosed that it recorded a $43 million reduction in revenue due to a change in...
2025-11-18 4:48 PM EST
Class Action Filed Against Synopsys, Inc. (SNPS) Over Securities Violations - Contact Levi & Korsinsky Today
New York, New York--(Newsfile Corp. - November 18, 2025) - If you suffered a loss on your Synopsys, Inc. (NASDAQ: SNPS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/synopsys-inc-lawsuit-submission-form?prid=178006&wire=5&utm_campaign=29 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder...
2025-11-18 4:27 PM EST